CHEK1 and small cell lung carcinoma: Recent studies have suggested that MYC-amplified SCLC may be sensitive to aurora kinase inhibitor (alisertib) and CHK1 inhibitors,10 suggesting a combinational strategy with drugs that target SCLC-NE populations for SCLC treatment.